StayBred VL5

StayBred VL5
Item# staybred
Availability: Yes
Not available online. Please call for shipping information.

Product Description

STAYBRED™ VL5 Injectable


STAYBRED™ VL5 is a suspension of inactivated Campylobacter fetus, Leptospira canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona. STAYBRED VL5 contains Amphigen™, a patented oil-in-water lecithin emulsion that enhances and prolongs the immune response while minimizing injection-site reactions and carcass trimout.

Approved Uses

STAYBRED VL5 is approved for: •Vaccination of healthy cows and heifers as an aid in preventing campylobacteriosis (vibriosis) caused by Campylobacter fetus, and leptospirosis caused by Leptospira canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona. Key Features

•Helps prevent two of the most common bovine reproductive diseases —campylobacteriosis (vibriosis) and leptospirosis.

•Preventive vaccination is the most cost-effective way of controlling two reproductive diseases that can be difficult to detect, particularly in adult cattle. Campylobacteriosis and leptospirosis can silently reduce herd productivity due to open cows, smaller calf crops, delayed conception, and a strung-out calving season.

•Efficacy of each of the Campylobacter and Leptospira components in STAYBRED VL5 was confirmed by challenge-of-immunity. Serologic tests determined that there was no immunologic interference among the components in STAYBRED VL5. Packaging

10- and 50-dose vials

Dosage and Administration

General Directions: Vaccination of healthy cows and heifers is recommended. Shake well. Aseptically administer 2 mL intramuscularly. In accordance with Beef Quality Assurance guidelines, this product should be administered in the muscular region of the neck.

Primary Vaccination: Administer two 2-mL doses 2–4 weeks apart to all breeding cows and heifers 30–60 days before exposure or being added to the herd.

Revaccination: Annual revaccination with a single dose is recommended.

Good animal husbandry and herd health management practices should be employed.


•Store at 2°–7° C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.

•Use entire contents when first opened.

•Sterilized syringes and needles should be used to administer this vaccine.

•Do not vaccinate within 21 days before slaughter.

•Occasional hypersensitivity reactions may occur up to 18 hours postvaccination. While this event appears to be rare overall, dairy cattle may be affected more frequently than other cattle.

•As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

•This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.